NEW YORK, Aug 14 – Exelixis of South San Francisco, Calif., has announced an agreement with Elan Pharmaceuticals to develop a compound library, marking Exelixis’ initial chemistry deal.

“This is our first chemistry-focused collaboration and it validates the quality of the discovery organization, while offsetting some of the cost of building our large high throughput screening compound library for drug discovery at Exelixis,” George Scangos, Exelixis’s CEO, said in a statement released Monday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.